

November 17, 2025

Kidswell Bio Corporation (TSE:4584)

S-Quatre Corporation

Interim Results of SHED Clinical Study for Children with Cerebral Palsy Disclosed by Nagoya University

Tokyo, November 17, 2025 – S-Quatre Corporation, a subsidiary of Kidswell Bio Group, is engaged in the research and development of novel cell-based therapies (regenerative medicine products) using stem cells from human exfoliated deciduous teeth (SHED), with the aim of developing new treatments for pediatric and rare diseases for which no effective therapies currently exist.

Among these efforts, one of the key initiatives is the clinical study led by Nagoya University, titled “*A clinical trial to evaluate the safety and tolerability of autologous stem cells from human exfoliated deciduous teeth in children with cerebral palsy.*” On November 14, the interim results of this study was disclosed by Nagoya University in a preprint publication* (<https://www.researchsquare.com/article/rs-8013498/v1>).

The paper reports data up to 12 weeks after administration, confirming the safety and tolerability of autologous SHED treatment. In addition, the results suggest potential improvements in the motor functions of participating patients.

These findings will also be presented at the upcoming Luncheon Seminar during the 12th Annual Meeting of the Japanese Society of Pediatric Physical Therapy on December 21, 2025, by Yoshiaki Sato, MD, PhD, Chief Director of the Maternity and Perinatal Care Center at Nagoya University Hospital.

The final 52-week safety and efficacy evaluations for the first and second patients have already been completed, and the third patient will continue to be followed through the 52-week period.

The Kidswell Bio Group remains committed to advancing our research and development initiatives with the goal of delivering innovative therapies to patients and families living with cerebral palsy and other intractable diseases.

*A preprint is a manuscript made publicly available prior to formal peer review to quickly share research findings promptly and gather broader feedback from the academic community. Its content may be revised or updated before formal publication following peer review.

- 12th Annual Meeting of the Japanese Society of Pediatric Physical Therapy
<https://jsppt-12th.org/> (Japanese only)

- Related release

[Administration Completed in All Three Patients in Clinical Study Using SHED for the Treatment of Pediatric Cerebral Palsy](#), June 24, 2025

[SHED Clinical Study for Cerebral Palsy Data Safety Monitoring Board Confirms "No Safety Concerns"](#), October 7, 2025

Disclaimer: This English translation is provided for reference purposes only. Should any discrepancies arise between this translation and the original Japanese document, the original Japanese document shall take precedence.